Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

2338 - Impact of response to preoperative chemotherapy on the outcome of pulmonary metastasectomy for colorectal cancer: Results of a retrospective multicenter study


21 Oct 2018


Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology


Surgical Oncology

Tumour Site

Colon and Rectal Cancer


Takehiro Okumura


Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281


T. Okumura1, N. Boku2, T. Hishida3, Y. Ohde4, Y. Sakao5, K. Yoshiya6, M. Higashiyama7, K. Kameyama8, H. Adachi9, K. Shiomi10, M. Kanzaki11, M. Yoshimura12, M. Matsuura13, Y. Hata14, F. Chen15, K. Yoshida16, H. Sasaki17, I. Hyodo18, K. Mori19, H. Kondo20

Author affiliations

  • 1 Surgery, Teikyo University School Of Medicine, University Hospital Mizonokuchi, 213-8507 - Kanagawa/JP
  • 2 Gastrointesitnal Medical Onclogy, National Cancer Center Hospital, Tokyo/JP
  • 3 Thoracic Surgery, Keio University School of Medicine, Tokyo/JP
  • 4 Thoracic Surgery, Shizuoka Cancer Center, Shizuoka/JP
  • 5 Thoracic Surgery, Aichi Cancer Center Hospital, Nagoya/JP
  • 6 Chest Surgery, Niigata Cancer Center Hospital, Niigata/JP
  • 7 Thoracic Surgery, Osaka International Cancer Center, Osaka/JP
  • 8 Thoracic Surgery, Kurashiki Central Hospital, Okayama/JP
  • 9 Thoracic Surgery, Hokkaido Cancer Center, Hokkaido/JP
  • 10 Thoracic Surgery, Kitasato University School of Medicine, Kanagawa/JP
  • 11 Surgery I, Tokyo Women's Medical University, Tokyo/JP
  • 12 Thoracic Surgery, Hyogo Cancer Center, Hyogo/JP
  • 13 Chest Surgery, Hiroshima City Hospital, Hiroshima/JP
  • 14 Surgery, Toho University School of Medicine, Tokyo/JP
  • 15 Thoracic Surgery, Kyoto University Graduate School of Medicine, Kyoto/JP
  • 16 Thoracic Surgery, Shinshu University School of Medicine, Nagano/JP
  • 17 Immunology, Oncology And Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya/JP
  • 18 Gastroenterology, University of Tsukuba, 305-8577 - Tsukuba/JP
  • 19 Clinical Trial Coordination Office Biostatistician, Shizuoka Cancer Center Hospital, 4118777 - Shizuoka/JP
  • 20 Thoracic Surgery, Kyorin University, Tokyo/JP


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2338


The benefit of preoperative chemotherapy (pre-CT) and metastasectomy for pulmonary metastasis (PM) from colorectal cancer (CRC) (PM-CRC) are unclear due to a lack of enough studies. However, there are some patients who receive chemotherapy after PM detection and subsequently undergo metastasectomy in clinical practice. The aim of this study was to investigate the impact of response to pre-CT on the outcome of pulmonary metastasectomy for PM-CRC.


The subjects were 92 patients, who received pre-CT before metastasectomy for PM-CRC, identified from the 1237 patients whose PM-CRC were curatively resected at 46 institutions in Japan between 2004 and 2008.


Twenty-six (28%) patients initially judged to have inoperable PM underwent chemotherapy leading to conversion to be resectable and subsequently received metastasectomy. The remaining 66 patients initially judged to have operable PM received pre-CT and subsequently underwent metastasectomy. Fifty-six (61%) patients received fluoropyrimidine based regimens combined with oxaliplatin or irinotecan, and most of the remaining 26 received tegafur/uracil. Pre-CT yielded partial response (PR), stable disease (SD) and progressive disease (PD) in 28 (30%), 26 (28%) and 38 (42%) patients, respectively. At metastasectomy, the proportions of patients with extrathoracic lesion, multiple PMs, and abnormal carcinoembryonic antigen level were 34, 58, and 40%, respectively. Wedge resection was the most frequent (62%) surgical procedure. The five-year disease-free (DFS) and overall survival (OS) rate of the all 92 patients were 25.1% (95% CI 16.4-34.7) and 45.4% (33.4-56.7). The five-year DFS rates of the patients with PR/SD and PD during pre-CT were 28.2% (16.5-41.1) and 20.6% (9.2-35.2), and those of OS were 58.1% (40.8-71.9) and 27.5% (12.9-44.3), respectively. By multivariate analysis, independent prognosticators were two or less PMs (HR = 0.56, 95% CI 0.33-0.94; p = 0.029) for DFS, and performance status 0 (0.44, 0.22-0.90; 0.024) and PR/SD during pre-CT (0.33, 0.18-0.61; < 0.001) for OS.


Response to Pre-CT had some impacts on OS after metastasectomy for PM-CRC: better in the patients with PR/SD compared to PD.

Clinical trial identification

Legal entity responsible for the study

Nonprofit Organization Tsukuba Cancer Clinical Trial Group.


Non-profit organization Tsukuba Cancer Clinical Trial Group.

Editorial Acknowledgement


N. Boku: Honoraria: Ono, BMS, Chugai, Merck Serono, Yakult, Eli Lilly companies. I. Hyodo: Honoraria: Taiho, Chugai, Daiichi-Sankyo, Yakult-Honshya companies. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.